TrkA kinase inhibitors, compositions and methods thereof

US9896447B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Andrew Cooke · Doylestown, US
• Craig A. Stump · Pottstown, US
• Xu-Fang Zhang · Dresher, US
• Chun Sing Li · Shanghai, CN
• Qinghua Mao · Shanghai, CN

Key dates

• Filing date: Sep 17, 2014
• Grant date: Feb 20, 2018
• Expiry date: Sep 17, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention is directed to benzyl urea compounds of formula (I) which are tropomyosin-related kinase (Trk) family protein kinase inhibitors, and hence may be useful in the treatment of pain, inflammation, cancer, restenosis, atherosclerosis, psoriasis, thrombosis, a disease, disorder, injury, or malfunction relating to dysmyelination or demyelination or a disease or disorder associated with abnormal activities of nerve growth factor (NGF) receptor Trk-A, Trk-B and/or Trk-C.